Healthcare providers are a trusted resource for cancer patients. The INHERIT Study is interested in trying to better understand the genetic risk for lung cancer. This includes patients and families with germline mutations in EGFR, HER2, and other genes–as well as families with histories of lung cancer who have not had genetic testing or have not been found to carry any germline mutations. We hope that you will encourage your patients who may meet the criteria listed below to enroll in the INHERIT Study to help us improve care for these populations.
Clinical resources
Our study team is happy to discuss appropriate follow-up testing and other resources for your patient’s management and care. Please contact us if you would like to review any patient cases and learn about available resources.
Study goals
While the genetic risk for cancers such as breast, ovarian, colon, and prostate cancer has been studied extensively, relatively little is known about any genetic risk for developing lung cancer. This is true for cases related to tobacco exposure, and especially for those that are not. In the INHERIT Study, we will study patients and families with either known germline mutations or elevated rates of lung cancer, and try to understand the basis for any inherited or genetic risk.
Our goals are to learn more about the genetic risk for lung cancer, how to better predict lung cancer risk in the context of family history or certain germline mutations, and ways to employ potential lung cancer screening in these populations.
To achieve these goals, we need to enroll as many individuals with potentially elevated genetic risk as possible. If your patients request your help with obtaining their pertinent medical records, or paraffin or blood specimens for the study, please help if you can. Please contact our study staff for assistance.
Eligible patients
If any one of the following apply, your patients may be eligible to participate in the INHERIT Study if they:
- Have been found to carry a germline mutation in EGFR (T790M or other) or HER2
- Have a relative with a germline EGFR or HER2 mutation
- Have a first-degree relative or multiple family members with lung cancer
- Have been diagnosed with one or more primary cancers in addition to lung cancer
How to refer patients
Please share our website with your patients, and encourage them to fill out our form or contact us directly at our main study site via the information below.
Questions?
If you have any questions about the study, please reach out to the INHERIT Study team at our primary site:
INHERIT Study team
inheritstudy@dfci.harvard.edu
617-632-2179
Boston, MA
